Cosentyx secukinumab: Additional Phase IIIb data

Additional data from the double-blind, international Phase IIIb CLEAR trial in 669 patients with moderate to severe plaque psoriasis showed that Cosentyx led to a PASI 90 response rate at week 52, a secondary endpoint, of 76.2% vs. 60.6% for Stelara ustekinumab (p<0.0001). An exploratory analysis showed that Cosentyx led to a PASI 100 response rate at week 52 of 45.9% vs. 35.8% for Stelara (p=0.0103). Additionally, a significantly greater proportion of patients receiving Cosentyx had Dermatology Life Quality Index (DLQI) responses of 0 or 1 vs. Stelara (71.6% vs. 59.2%, p=0.0008). Patients received 300 mg subcutaneous Cosentyx or subcutaneous Stelara at weeks 0, 1, 2 and 3 followed by once-monthly dosing through week 48. Data were presented at the American Academy of Dermatology meeting in Washington, D.C. ...